Beyond the CTD: What European Manufacturers Should Know Before an ANDA Submission in the US

For European pharmaceutical manufacturers, entering the US market may appear to be a natural extension of an established product portfolio. Existing development data, manufacturing processes and an EU Common Technical Document (CTD) provide a valuable starting point. However, transferring an existing dossier to the US regulatory environment is not simply an administrative exercise. Differences in regulatory pathways, reference products and Chemistry, Manufacturing and Controls (CMC) documentation can have a significant impact on submission readiness.

Choosing the Right Regulatory Pathway

The first strategic decision is whether the product qualifies for an Abbreviated New Drug Application (ANDA) under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

A traditional ANDA relies on the FDA's previous finding of safety and effectiveness for a reference listed drug and generally requires the proposed product to meet specific criteria for sameness, including dosage form, strength, route of administration and active ingredient, as applicable. Demonstration of bioequivalence is a central element of the development strategy.

Reference Products, Patents and Exclusivity

For an ANDA, understanding the relevant US Reference Listed Drug (RLD) and Reference Standard (RS) is fundamental. The FDA's Orange Book and applicable Product-Specific Guidance (PSG) should be reviewed at an early stage to understand the regulatory landscape for the proposed product.

Patent and exclusivity considerations are an integral part of ANDA planning. Applicants should review the FDA Orange Book early and determine the appropriate patent certification for each relevant listed patent. Depending on the certification, patent status may affect the timing of FDA approval and, in the case of a Paragraph IV certification, may trigger patent litigation and potential 180-day generic drug exclusivity considerations.

The lesson is simple: identify the US regulatory reference product before key development decisions become difficult or expensive to change.

Module 1: More Than an Administrative Difference

One of the most important differences between an EU and a US submission lies in Module 1. Although both regions use the CTD structure, Module 1 is region-specific and cannot simply be transferred from one dossier to the other.

The US Module 1 contains specific administrative and regulatory information, including US-specific application forms, patent and exclusivity information, and documentation relating to the reference product. For example, when an applicant relies on an FDA Drug Master File (DMF), the required Letter of Authorization must be provided as part of the application and handled in accordance with FDA submission requirements. This differs from the EU ASMF procedure, where the Active Substance Master File holder submits the relevant Letter of Access to the authority.

The CMC Gap: Why an EU Dossier May Not Be US-Ready

Existing European development data can provide an excellent foundation for a US program. However, the fact that a product has successfully met European requirements does not automatically mean that the FDA will accept the same development approach.

The CTD provides a common structure, but the required level of detail and supporting documentation can differ between jurisdictions. FDA's ANDA Submissions: Content and Format of Abbreviated New Drug Applications guidance is therefore an important reference when preparing a US submission.

Analytical method documentation also deserves attention. FDA expects appropriate verification of compendial methods and validation of in-house methods, with supporting reports included in the relevant CTD sections. An EU dossier containing only a validation summary may therefore require additional documentation before it is ready for US submission.

API Documentation: CEP or DMF?

European manufacturers frequently rely on a Certificate of Suitability (CEP) or an Active Substance Master File (ASMF) to support their EU applications. These mechanisms should not be assumed to replace US-specific documentation requirements.

For a US application, drug substance information may be provided directly in the application or referenced through an appropriate FDA Drug Master File (DMF), commonly a Type II DMF for an API. Where a DMF is referenced, the required Letter of Authorization must be provided in accordance with FDA requirements and the applicable submission procedures.

The DMF's readiness, the API manufacturer's documentation and the arrangements for maintaining the reference throughout the application lifecycle should be confirmed well before submission.

Manufacturing and FDA Inspection Readiness

Manufacturing sites outside the US remain subject to applicable FDA requirements. Manufacturers should verify that relevant establishment information, registration obligations, quality systems and inspection readiness are addressed. The CMC package must accurately describe the manufacturing process, controls and sites involved in producing the proposed drug product.

Inspection readiness should be integrated into the development program, not initiated only after an inspection has been announced.

Engage with FDA Before Submission

One of the most valuable opportunities for a company entering the US market is the possibility of obtaining FDA feedback before the application is submitted.

Early FDA interaction can help resolve questions about the proposed development strategy. Depending on the product and the issues involved, Pre-ANDA meetings or controlled correspondence may be appropriate, particularly for complex generics or uncertain bioequivalence approaches.

Such interactions can help clarify expectations before significant resources are committed, although they do not replace the applicant's responsibility to provide a complete and scientifically justified application.

Conclusion

For European manufacturers, the US market offers significant opportunities, but successful market entry requires more than transferring an existing European dossier into a US submission.

Manufacturers should assess the regulatory pathway, reference product, patent landscape, bioequivalence strategy and US-specific CMC documentation requirements early.

A structured EU-US gap assessment can identify missing reports, additional data needs and administrative requirements before submission. The most effective approach is therefore to treat the US regulatory strategy as an integral part of product development rather than as the final step after European development has been completed.

Image notice: The illustrative and header images were generated using AI and do not depict real people, places, or events. The portrait photographs show real people.